Targeting these factors through combinatorial strategies, such as blockade of IL‐10 or CXCR4, may enhance CAR T‐cell efficacy and overcome therapeutic resistance in CLL patients. Here, CXCR4 is linked to B-cell chronic lymphocytic leukemia.